BioDelivery Sciences International, Inc. and Meda AB today announced approval from the U.S. FDA to market ONSOLIS™ (fentanyl buccal soluble film), formerly referred to as BEMA™ Fentanyl, for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
The details can be read here.
No comments:
Post a Comment